BIOC) shares are trading higher on Thursday after the company announced an agreement with Aegea Biotechnologies to develop new, highly sensitive PCR-based Covid-19 assay.
Biocept is an early commercial-stage molecular oncology diagnostics company. It develops and commercializes proprietary circulating tumor cells and circulating tumor DNA assays utilizing a standard blood sample. The company’s lung, breast, and gastric cancer assays provide information to oncologists and other physicians that enable them to select personalized treatment for their patients based on detailed data on the characteristics of tumors.
Its products include CEE-Sure BCT, and Target Selector Kits. Geographically, it operates through the United States, which is also the revenue generation region for the group.
Biocept shares were trading up 25.80% at $1.12 time of publication on Thursday. The stock has a 52-week high of $1.30 and a 52-week low of 21 cents.
View Article Origin Here